Key insights
- Increased M&A activity in the biotech sector, driven by patent expirations and the FDA, suggests potential upside for smaller biotech companies. Large pharmaceutical companies like Lilly and Pfizer are actively acquiring assets, particularly in GLP, oncology, and T-cell therapy. This trend could lead to higher valuations and acquisition premiums for target companies, benefiting investors in the short to medium term.
Are any of you folks into biotech M&A?? I do it for a living & always down for good M&A talk. My group hit 6 deals in the last 30 days 2 more loaded waiting for official announcements. The FDA & the 2030 patent cliff make M&A a must for big pharma! The premiums are real and the AVG cap has been around 4Bil. There is an urgency in the Pharma world & building assets in house is time consuming & expensive it cost much less to just write a check & the big five are flush with cash Lilly alone has made three big deals and PFE is rumored in two right now. GLP oncology and T-Cell therapy are some of the hottest spaces